Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cetirizine Hydrochloride

FDA-approved product (tablet, oral), marketed as Cetirizine Hydrochloride, Cetirizine Hydrochloride Allergy, Cetirizine Hydrochloride Hives and 11 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Cetirizine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Allergic conjunctivitis
  • Allergic disease
  • Allergic rhinitis
  • Eye allergy
  • Nasal congestion
  • Pruritus
  • Rhinitis, Allergic, Perennial
  • Seasonal allergic rhinitis
  • Urticaria

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Piperazine derivatives; Other antiallergics
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA43.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cetirizine Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cetirizine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03735)

    NCT00751218 · start 2004-05-06

    Registered record
    Registry ID
    NCT00751218
    Conditions
    Urticaria
    Interventions
    desloratadine; placebo; cetirizine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-05-06
    Completion
    2005-05-24
    Enrolment
    174

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrticaria
    Interventiondesloratadine; placebo; cetirizine
    PhasePhase 4
    Registry statusCompleted

  • Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03181)

    NCT00794495 · start 2002-12

    Registered record
    Registry ID
    NCT00794495
    Conditions
    Seasonal Allergic Rhinitis; Perennial Allergic Rhinitis
    Interventions
    Desloratadine 5 mg (Clarinex); Cetirizine (Zyrtec)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-12
    Completion
    2003-07
    Enrolment
    122

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeasonal Allergic Rhinitis; Perennial Allergic Rhinitis
    InterventionDesloratadine 5 mg (Clarinex); Cetirizine (Zyrtec)
    PhasePhase 4
    Registry statusCompleted

  • Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03182)

    NCT00794599 · start 2002-12

    Registered record
    Registry ID
    NCT00794599
    Conditions
    Seasonal Allergic Rhinitis; Perennial Allergic Rhinitis
    Interventions
    Desloratadine 5 mg (Clarinex); Cetirizine (Zyrtec)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-12
    Completion
    2003-08
    Enrolment
    118

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeasonal Allergic Rhinitis; Perennial Allergic Rhinitis
    InterventionDesloratadine 5 mg (Clarinex); Cetirizine (Zyrtec)
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of Cetirizine Tablets Versus Ketotifen Dry Syrup in Children With Perennial Allergic Rhinitis

    NCT00639587 · start 2002-08

    Registered record
    Registry ID
    NCT00639587
    Conditions
    Rhinitis, Allergic, Perennial
    Interventions
    Ketotifen; Cetirizine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-08
    Completion
    2003-03
    Enrolment
    149

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis, Allergic, Perennial
    InterventionKetotifen; Cetirizine
    PhasePhase 3
    Registry statusCompleted

  • Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine HCl Syrup vs. Loratadine Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR)

    NCT02932774 · start 2001-03

    Registered record
    Registry ID
    NCT02932774
    Conditions
    Allergic Rhinitis; Hay Fever; SAR; Rhinitis, Allergic, Seasonal
    Interventions
    Cetirizine; Loratadine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2001-03
    Completion
    2001-07
    Enrolment
    683

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Rhinitis; Hay Fever; SAR; Rhinitis, Allergic, Seasonal
    InterventionCetirizine; Loratadine; Placebo
    PhasePhase 4
    Registry statusCompleted